4 ms·
There are a wide variety of life courses exhibited in the natural world, when plotting mortality risk over time. The human early start on an exponential increas
by reasonattlm 9y ago
There are a wide variety of life courses exhibited in the natural world, when plotting mortality risk over time. The human early start on an exponential increase is just one of them. Flies that reach a mortality risk plateau in late life is another - they just stop aging, they don't get any more damaged in ways that cause mortality than they already are. More complex organisms don't seem to exhibit this phenomenon, but the data for humans is pretty sparse at the ages of interest.
Naked mole rats and humans age for the same underlying reasons, the same types of accumulated damage. The difference in outcomes in terms of the shape of the mortality curve no doubt has to do with quality of repair mechanisms and resilience to particular forms of damage. Naked mole rats have less error-prone DNA replication, repair, and protein manufacture processes, a lack of lingering senescent cells pumping out inflammatory and destructive signals, a mitochondrial composition that is more resilient to oxidative stress (and they have plenty of oxidative damage, judging from the usual markers, they just seem to shrug it off; it doesn't cause further problems). The net result of this is that they do pretty well then fall off a cliff at the end.
It is interesting to speculate on what the cliff might be, a high threshold of damage needed to break an important repair mechanism, or a slowly accumulating form of damage that only really hurts the mole-rat at high levels, for example, but this is probably not very relevant to human medicine.
We know why humans age. We know what the damage is. We don't need to poke around in other species for further illumination in order to make progress towards rejuvenation - we won't learn anywhere near as much as we will from selective repair of the damage in humans or in mammals that are similar to humans. We don't need to improve human damage repair systems (comparatively hard) when we can repair damage (comparatively easy). It clearly takes a few decades for pathological levels of damage to arise, which gives plenty of time to deal with it through periodic applications of therapy, given a working repair biotechnology.
The comparative biology of aging is pure science, unlikely to produce meaningful applications of medicine when compared with other courses of action.
- igravious 9y agoIANAGB and your meta-explanation makes total sense _but_ I'm given to believe that improving human damage repair systems would require gene therapy and this is becoming an easier and easier technique over time–isn't this what powers a lot of medical breakthroughs now? Am I wrong in believing this? Are you definitively asserting that repairing damage is going to be comparatively simpler than improving damage repair systems for the foreseeable future?
- reasonattlm 9y agoOnly some of the damage repair methods require gene therapy, and in the case of allotopic expression to work around mitochondrial damage that is already demonstrated in human trials by Gensight. You should look over the linked sub-pages here for an overview of the types of damage and approaches to repair. http://www.sens.org/research/introduction-to-sens-research http://www.sens.org/research/introduction-to-sens-research I'd be more concerned about stem cell replacement therapies and lipofuscin removal as categories than anything requiring gene therapy, since in both cases there are a lot of targets and a lot of work to do. For things like senescent cells and glucosepane cross-links, small molecule therapies will work (and already exist in the former case). In fact all targeted cell killing and specific molecule breakdown needs can probably be addressed sufficiently well via pharmaceuticals for a first generation effort.
- igravious 9y agoThanks for the pointers.